Markers of Disease Progression and Gait Within the Parkinsonian Population — Gait'N'Park  

Parkinson Disease Clinical Trial

Official title: A Prospective Study on Markers of Disease Progression and Gait Within the Parkinsonian Population

Status Recruiting

Clinical Trial Summary

The aim of the project is to evaluate disease progression of patients with Parkinsonian syndrome of various severity through regular home-based gait parameters analysis.

We identified several steps in this project:

1. Acquisition of gait data in 120 patients with Parkinsonism at different stages in hospital and ecological condition (during 10 days at home), in a repetitive manner:

1. 30 Early PD patients, before 3 years of disease duration (MDS criteria, 2018)

2. 30 PD patients with motor fluctuations (5 to 8 years of disease duration) (MDS criteria, 2018)

3. 30 PD patients with FoG (10 years of disease duration) (MDS criteria, 2018)

4. 30 patients with MSA (less than 5 years after the first symptom)

2. Control groups will be composed by 30 healthy volunteers Correlation analysis with clinical measurements and biomarkers, namely blood biomarkers for neurodegeneration (4HN, NFLT …) and multimodal MRI repeated assessments (Iron overload, inflammation and degeneration) and genetic panel for common haplotypes involved in Parkinsonism.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Disease Progression
• Parkinson Disease

• NCT number: NCT04653688
• Study type: Interventional
• Source: University Hospital, Lille
• Contact: Caroline Moreau, MD,PhD
• Phone: 0320445962
• Email: caroline.moreau@chru-lille.fr
• Status: Recruiting
• Phase: N/A
• Start date: December 22, 2020
• Completion date: January 2024